^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ONCR-177

    i
    Other names: ONCR-177, oncolytic herpes simplex virus, oHSV
    Associations

    News

    Trials
    Company:
    Oncorus
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor, IL-12 stimulant, CCL4 stimulant, FLT3 modulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    KEYNOTE-B73: Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (clinicaltrials.gov)
    P1, N=66, Terminated, Oncorus, Inc. | N=132 --> 66 | Trial completion date: Jul 2028 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> May 2023; Terminated due to Oncorus portfolio reprioritization
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • ONCR-177
    over4years
    [VIRTUAL] mONCR-177 oncolytic virotherapy stimulates anti-tumor and anti-viral immunogenicity (AACR-II 2020)
    Treatment results in increased infiltrating immune cells, activation, and polyfunctional CD8+ T cells. These results highlight the dual modality mechanism of action of mONCR-177 treatment through direct tumor cell killing and immune stimulation through the antiviral response, and their enhancement by the immune stimulatory transgenes.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • CCL4 (Chemokine (C-C motif) ligand 4)
    |
    PD-1 expression
    |
    ONCR-177